Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Chronic Lymphocytic Leukemia
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Type
Interventional
Phase
Phase 1
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Prevention

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

PRIMARY OBJECTIVE: I. To determine the seroprotection and seroconversion rates after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation. SECONDARY OBJECTIVES: I. To characterize influenza-specific plasmablasts and memory B cells after influenza vac...

PRIMARY OBJECTIVE: I. To determine the seroprotection and seroconversion rates after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation. SECONDARY OBJECTIVES: I. To characterize influenza-specific plasmablasts and memory B cells after influenza vaccination in patients with lymphoma receiving active treatment or in follow up observation. II. To investigate the longevity of humoral immunity to influenza virus in patients with lymphoma receiving active treatment or in follow up observation. III. To assess the timing and strength of the peak immune response to influenza vaccination. IV. To assess the effect of different lymphomas and treatment modalities in the immune response to influenza vaccination. OUTLINE: Patients receive seasonal inactivated influenza vaccine intramuscularly (IM) at day 0. After completion of study treatment, patients are followed up at days 7, 14, 28, 90, and 180

Tracking Information

NCT #
NCT03501576
Collaborators
Not Provided
Investigators
Principal Investigator: Andres Chang, MD, PhD Emory University
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024